Sai Parenterals approves Q2 and H1 results; buyout of SP Analytics' remaining 25% approved
Sai Parenterals · Pharmaceuticals & Biotechnology
Key highlights
- Approved unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026
- Board approved acquiring the remaining 25% equity in SP Analytics Pvt Ltd for Rs.25,000 cash, to complete on or before 31.12.2026
- Company completed acquisition of 60% equity in Saicriti Pharma Pvt Ltd, which has become a subsidiary
Why it's rated major development: the year-on-year change is 66% (50% or more)
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
Board Meeting Outcome for Outcome Of Board Meeting Held On 1St November, 2026
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Sai Parenterals
- Financial resultsMajor developmentSai Parenteral's approves Sep 2026 quarter results and SP Analytics stake acquisition
- Acquisition / mergerNotableSai Parenterals Limited reports Q2 & H1 FY27 results and strategic updates
Other acquisition / merger filings this fortnight
- IndiGrid Infrastructure Trust Q2 FY27 Earnings Conference Call Transcript Released
- Cubical Financial Services Ltd announces promoter reclassification post open offer
- Novus Loyalty Limited approves acquisition of AutoPe Payment Solutions via share swap
- Shish Industries Limited files Composite Scheme of Amalgamation proposal
- Jubilant Ingrevia Limited updates on acquisition of 40% stake in Zettaone Technologies
- NHC Foods approves quarter results, 99.98% Sachmaas Foods investment, two appointments
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.